Excessive treatment failures in patients with parameningeal rhabdomyosarcoma with reduced-dose cyclophosphamide and delayed radiotherapy

John T. Lucas; Alberto S. Pappo; Jianrong Wu; Daniel J. Indelicato; Matthew J. Krasin

doi:10.1097/MPH.0000000000001188

Excessive treatment failures in patients with parameningeal rhabdomyosarcoma with reduced-dose cyclophosphamide and delayed radiotherapy

John T. Lucas, Alberto S. Pappo, Jianrong Wu, Daniel J. Indelicato, Matthew J. Krasin

Internal Medicine

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Pediatric patients with parameningeal rhabdomyosarcoma and high-risk features are recommended to receive radiotherapy at initiation of protocol therapy due to concerns about the increased risk of local and leptomeningeal failure from treatment delay. We report our early experience on a multi-institutional prospective trial incorporating delayed primary site radiation and reduced dose cyclophosphamide in all patients with parameningeal tumors. We observed an excessive number of locoregional treatment failures following this approach and have subsequently amended our trial to move radiation therapy upfront for those patients with high-risk features. We suggest that investigators should be vigilant for treatment failure given our early prospective experience with delayed radiotherapy and reduced dose cyclophosphamide.

Original language	English
Pages (from-to)	387-390
Number of pages	4
Journal	Journal of Pediatric Hematology/Oncology
Volume	40
Issue number	5
DOIs	https://doi.org/10.1097/MPH.0000000000001188
State	Published - Jul 1 2018

Bibliographical note

Funding Information:
Received for publication June 7, 2017; accepted December 21, 2017. From the Departments of *Radiation Oncology; †Oncology; ‡Biostatistics, St Jude Children’s Research Hospital, Memphis, TN; and §Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL. Supported in part by the St Jude Children’s Research Hospital Cancer Center Grant P30CA021765. The authors declare no conflict of interest. Reprints: John T. Lucas Jr, MS, MD, Department of Radiation Oncology, St Jude Children’s Research Hospital, 262 Danny Thomas Place, MS 210, Memphis, TN 38105-3678 (e-mail: john.lucas@stjude.org). Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

cyclophosphamide
parameningeal tumors
radiotherapy
rhabdomyosarcoma

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1097/MPH.0000000000001188

Cite this

@article{ff9fc94cd7fb4b1bad9736c1ed294736,

title = "Excessive treatment failures in patients with parameningeal rhabdomyosarcoma with reduced-dose cyclophosphamide and delayed radiotherapy",

abstract = "Pediatric patients with parameningeal rhabdomyosarcoma and high-risk features are recommended to receive radiotherapy at initiation of protocol therapy due to concerns about the increased risk of local and leptomeningeal failure from treatment delay. We report our early experience on a multi-institutional prospective trial incorporating delayed primary site radiation and reduced dose cyclophosphamide in all patients with parameningeal tumors. We observed an excessive number of locoregional treatment failures following this approach and have subsequently amended our trial to move radiation therapy upfront for those patients with high-risk features. We suggest that investigators should be vigilant for treatment failure given our early prospective experience with delayed radiotherapy and reduced dose cyclophosphamide.",

keywords = "cyclophosphamide, parameningeal tumors, radiotherapy, rhabdomyosarcoma",

author = "Lucas, {John T.} and Pappo, {Alberto S.} and Jianrong Wu and Indelicato, {Daniel J.} and Krasin, {Matthew J.}",

note = "Funding Information: Received for publication June 7, 2017; accepted December 21, 2017. From the Departments of *Radiation Oncology; †Oncology; ‡Biostatistics, St Jude Children{\textquoteright}s Research Hospital, Memphis, TN; and §Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL. Supported in part by the St Jude Children{\textquoteright}s Research Hospital Cancer Center Grant P30CA021765. The authors declare no conflict of interest. Reprints: John T. Lucas Jr, MS, MD, Department of Radiation Oncology, St Jude Children{\textquoteright}s Research Hospital, 262 Danny Thomas Place, MS 210, Memphis, TN 38105-3678 (e-mail: john.lucas@stjude.org). Copyright {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved. Publisher Copyright: {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved.",

year = "2018",

month = jul,

day = "1",

doi = "10.1097/MPH.0000000000001188",

language = "English",

volume = "40",

pages = "387--390",

number = "5",

}

TY - JOUR

T1 - Excessive treatment failures in patients with parameningeal rhabdomyosarcoma with reduced-dose cyclophosphamide and delayed radiotherapy

AU - Lucas, John T.

AU - Pappo, Alberto S.

AU - Wu, Jianrong

AU - Indelicato, Daniel J.

AU - Krasin, Matthew J.

N1 - Funding Information: Received for publication June 7, 2017; accepted December 21, 2017. From the Departments of *Radiation Oncology; †Oncology; ‡Biostatistics, St Jude Children’s Research Hospital, Memphis, TN; and §Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL. Supported in part by the St Jude Children’s Research Hospital Cancer Center Grant P30CA021765. The authors declare no conflict of interest. Reprints: John T. Lucas Jr, MS, MD, Department of Radiation Oncology, St Jude Children’s Research Hospital, 262 Danny Thomas Place, MS 210, Memphis, TN 38105-3678 (e-mail: john.lucas@stjude.org). Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. Publisher Copyright: © 2018 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Pediatric patients with parameningeal rhabdomyosarcoma and high-risk features are recommended to receive radiotherapy at initiation of protocol therapy due to concerns about the increased risk of local and leptomeningeal failure from treatment delay. We report our early experience on a multi-institutional prospective trial incorporating delayed primary site radiation and reduced dose cyclophosphamide in all patients with parameningeal tumors. We observed an excessive number of locoregional treatment failures following this approach and have subsequently amended our trial to move radiation therapy upfront for those patients with high-risk features. We suggest that investigators should be vigilant for treatment failure given our early prospective experience with delayed radiotherapy and reduced dose cyclophosphamide.

AB - Pediatric patients with parameningeal rhabdomyosarcoma and high-risk features are recommended to receive radiotherapy at initiation of protocol therapy due to concerns about the increased risk of local and leptomeningeal failure from treatment delay. We report our early experience on a multi-institutional prospective trial incorporating delayed primary site radiation and reduced dose cyclophosphamide in all patients with parameningeal tumors. We observed an excessive number of locoregional treatment failures following this approach and have subsequently amended our trial to move radiation therapy upfront for those patients with high-risk features. We suggest that investigators should be vigilant for treatment failure given our early prospective experience with delayed radiotherapy and reduced dose cyclophosphamide.

KW - cyclophosphamide

KW - parameningeal tumors

KW - radiotherapy

KW - rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85049238467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049238467&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001188

DO - 10.1097/MPH.0000000000001188

M3 - Article

C2 - 29683960

AN - SCOPUS:85049238467

VL - 40

SP - 387

EP - 390

IS - 5

ER -

Excessive treatment failures in patients with parameningeal rhabdomyosarcoma with reduced-dose cyclophosphamide and delayed radiotherapy

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this